Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Treatment of stage IIIb/IV non-small cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatment.

Shi SB, Hu RH, Qi JL, Tang XY, Tian J, Li R, Chang CX.

Med Oncol. 2013;30(2):550. doi: 10.1007/s12032-013-0550-7. Epub 2013 Apr 11.

2.

Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer.

Mir O, Boudou-Rouquette P, Giroux J, Chapron J, Alexandre J, Gibault L, Ropert S, Coriat R, Durand JP, Burgel PR, Dusser D, Goldwasser F.

Lung Cancer. 2012 Jul;77(1):104-9. doi: 10.1016/j.lungcan.2012.01.014. Epub 2012 Feb 24.

PMID:
22364783
3.

A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.

Schuette WH, Gröschel A, Sebastian M, Andreas S, Müller T, Schneller F, Guetz S, Eschbach C, Bohnet S, Leschinger MI, Reck M.

Clin Lung Cancer. 2013 May;14(3):215-23. doi: 10.1016/j.cllc.2012.10.001. Epub 2013 Jan 16.

PMID:
23332288
4.

A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer.

Dittrich C, Papai-Szekely Z, Vinolas N, Sederholm C, Hartmann JT, Behringer D, Kazeem G, Desaiah D, Leschinger MI, von Pawel J.

Eur J Cancer. 2014 Jun;50(9):1571-80. doi: 10.1016/j.ejca.2014.03.007. Epub 2014 Apr 2.

PMID:
24703574
5.

[Pemetrexed alone versus pemetrexed combined with oxaliplatin as salvage therapy in stage IV lung adenocarcinoma].

Liu Y, Jiang Y, Gao Z, Wang X, Han B, Jiang L.

Zhongguo Fei Ai Za Zhi. 2011 Sep;14(9):704-9. doi: 10.3779/j.issn.1009-3419.2011.09.01. Chinese.

6.

Pemetrexed plus dendritic cells as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer who had treatment with TKI.

Hu RH, Shi SB, Qi JL, Tian J, Tang XY, Liu GF, Chang CX.

Med Oncol. 2014 Aug;31(8):63. doi: 10.1007/s12032-014-0063-z. Epub 2014 Jun 24.

PMID:
24958515
7.

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D.

J Clin Oncol. 2008 Jul 20;26(21):3543-51. doi: 10.1200/JCO.2007.15.0375. Epub 2008 May 27.

PMID:
18506025
9.

Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer.

Lee DH, Lee JS, Kim SW, Rodrigues-Pereira J, Han B, Song XQ, Wang J, Kim HK, Sahoo TP, Digumarti R, Wang X, Altug S, Orlando M.

Eur J Cancer. 2013 Oct;49(15):3111-21. doi: 10.1016/j.ejca.2013.06.035. Epub 2013 Jul 24.

PMID:
23890768
10.

A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.

Li N, Ou W, Yang H, Liu QW, Zhang SL, Wang BX, Wang SY.

Cancer. 2014 May 1;120(9):1379-86. doi: 10.1002/cncr.28591. Epub 2014 Jan 30.

11.

[Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer].

Hu X, Jiao S, Zhang S, Wang Z, Wang M, Huang C, Zheng R, Li K, Wang J, Wang Y, Ouyang X, Lv W, Cheng G, Hu C, Luo R, Sun Y.

Zhongguo Fei Ai Za Zhi. 2012 Oct;15(10):569-75. doi: 10.3779/j.issn.1009-3419.2012.10.02. Chinese.

12.

[Effects of EGFR-TKIs on sequential pemetrexed
for advanced pulmonary adenocarcinoma].

Wang X, Liu Y, Gao Z, Jiang Y, Han B, Jiang L.

Zhongguo Fei Ai Za Zhi. 2012 May;15(5):294-8. doi: 10.3779/j.issn.1009-3419.2012.05.08. Chinese.

13.
14.

Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.

Patel JD, Hensing TA, Rademaker A, Hart EM, Blum MG, Milton DT, Bonomi PD.

J Clin Oncol. 2009 Jul 10;27(20):3284-9. doi: 10.1200/JCO.2008.20.8181. Epub 2009 May 11.

PMID:
19433684
15.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M.

J Clin Oncol. 2013 Sep 20;31(27):3327-34. doi: 10.1200/JCO.2012.44.2806. Epub 2013 Jul 1.

PMID:
23816960
16.
17.

Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer.

Ahn MJ, Yang JC, Liang J, Kang JH, Xiu Q, Chen YM, Blair JM, Peng G, Linn C, Orlando M.

Lung Cancer. 2012 Aug;77(2):346-52. doi: 10.1016/j.lungcan.2012.03.011. Epub 2012 Apr 23.

PMID:
22534669
18.

Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials.

Zinner RG, Novello S, Peng G, Herbst R, Obasaju C, Scagliotti G.

Clin Lung Cancer. 2010 Mar 1;11(2):126-31. doi: 10.3816/CLC.2010.n.017.

PMID:
20199979
19.

[Comparison of the efficacy of second line EGFR TKIs followed by third line pemetrexed or the reverse sequence in the treatment of advanced lung adenocarcinoma].

Zhang RX, Cai DY, Hong TT, Wu XH, Hua D.

Zhonghua Zhong Liu Za Zhi. 2012 Feb;34(2):147-51. doi: 10.3760/cma.j.issn.0253-3766.2012.02.015. Chinese.

PMID:
22780936
20.

Phase II study of pemetrexed plus oxaliplatin for platinum-resistant advanced or metastatic non-small cell lung cancer patients.

Lee DH, Choi CM, Kim SW, Suh C, Lee JS.

Med Oncol. 2012 Jun;29(2):640-3. doi: 10.1007/s12032-011-9944-6. Epub 2011 Apr 16.

PMID:
21499804

Supplemental Content

Support Center